127 related articles for article (PubMed ID: 31988438)
21. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
22. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
[TBL] [Abstract][Full Text] [Related]
23. LGALS1 acts as a pro-survival molecule in AML.
Ruvolo PP; Ma H; Ruvolo VR; Zhang X; Post SM; Andreeff M
Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118785. PubMed ID: 32590026
[TBL] [Abstract][Full Text] [Related]
24. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
25. FOXM1 contributes to treatment failure in acute myeloid leukemia.
Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
[TBL] [Abstract][Full Text] [Related]
26. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
28. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
[TBL] [Abstract][Full Text] [Related]
29. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
30. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Guzman ML; Yang N; Sharma KK; Balys M; Corbett CA; Jordan CT; Becker MW; Steidl U; Abdel-Wahab O; Levine RL; Marcucci G; Roboz GJ; Hassane DC
Mol Cancer Ther; 2014 Aug; 13(8):1979-90. PubMed ID: 24934933
[TBL] [Abstract][Full Text] [Related]
31. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M
Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
[TBL] [Abstract][Full Text] [Related]
34. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
35. Chemoresistance in acute myeloid leukemia: An alternative single-cell RNA sequencing approach.
Cheng PL; Hsiao TH; Chen CH; Hung MN; Jhan PP; Lee LW; Wu TS; Tsai JR; Teng CJ
Hematol Oncol; 2023 Aug; 41(3):499-509. PubMed ID: 36790759
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
Ou J; Xu X; Deng S; Liang H; Cai Z; Li J; Huang Z; Tang B; Wang Z; Zhou Y; Liu X; Liu Q; Zhou H
Leuk Lymphoma; 2024 Feb; 65(2):219-227. PubMed ID: 37938093
[TBL] [Abstract][Full Text] [Related]
37. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
[TBL] [Abstract][Full Text] [Related]
38. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
[TBL] [Abstract][Full Text] [Related]
39. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
40. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Blagosklonny MV; Trostel S; Kayastha G; Demidenko ZN; Vassilev LT; Romanova LY; Bates S; Fojo T
Cancer Res; 2005 Aug; 65(16):7386-92. PubMed ID: 16103091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
